Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $115.00

Дата публикации: 10-08-2026 06:00:47

Halozyme Therapeutics (NASDAQ:HALO – Free Report) had its price objective boosted by HC Wainwright from $95.00 to $115.00 in a research report released on Friday,Benzinga reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock. Other equities research analysts have also issued reports about the company. UBS Group reaffirmed a “buy” rating […]

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Haemonetics (NYSE:HAE) Price Target Raised to $86.00	0	14.69	10-08-2026
2	Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $146.00	0	14.22	10-08-2026
3	Wall Street Zen Upgrades NovoCure (NASDAQ:NVCR) to Buy	0	8.24	10-08-2026
4	Arlo Technologies (NYSE:ARLO) Price Target Raised to $18.00	0	10.44	10-08-2026
5	Roivant Sciences (NASDAQ:ROIV) Price Target Raised to $42.00	0	11.84	10-08-2026
6	BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Raised to $114.00 at Canaccord Genuity Group	0	10.88	10-08-2026
7	Block (NYSE:XYZ) Price Target Raised to $125.00	0	13.75	10-08-2026
8	AMN Healthcare Services (NYSE:AMN) Price Target Raised to $35.00	0	10.79	10-08-2026
9	Monness Crespi & Hardt Raises Workday (NASDAQ:WDAY) Price Target to $202.00	0	14.78	10-08-2026
10	Wall Street Zen Downgrades Herbalife (NYSE:HLF) to Hold	0	7.41	10-08-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 11.48. Источник: www.americanbankingnews.com.